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Background: Pulmonary hypertension secondary to chronic elevation in left ventricular (LV) filling pressures is a common feature of advanced 
heart failure. This is often considered an exclusion criterion for transplantation. The aim of this study was to ascertain if the use of left venticular 
assist devices (LVADs) in patients with previously considered fixed pulmonary hypertension results in subsequent reversibility.
Methods: Fifty-seven patients implanted as both bridge to transplant (BTT) and destination therapy at a single center since February 2007 were 
studied.
Results: Of 57 patients studied, 26 underwent a vasodilator challenge at right heart catheterization prior to LVAD implantation. Three received 
pulsatile LVADs, the remainder continuous flow devices. Sodium nitroprusside (mean peak dose 2.4±1.6 μg/kg/min) was administered in 23 
patients and nitric oxide at a peak dose of 80 ppm in three patients. There were 14 responders and 12 non-responders. The hemodynamic effects of 
vasodilator challenge and subsequent LVAD implantation are shown in Figures 1 and 2.
Conclusions: LVAD therapy very effectively decreases pulmonary arterial pressures in patients previously identified to have either fixed 
or reversible pulmonary hypertension at right heart catheterization. Furthermore, PVR appears to normalize in both groups post LVAD 
placement, suggesting that LVAD therapy may render some patients who transplant ineligible due to high PVR potentially transplantable.
